PRISM BioLab Co

PRISM BioLab Co Liabilities

The The Liabilities of PRISM BioLab Co (206A.T) as of Nov 10, 2026 is 376.86 M JPY. In the previous year, The Liabilities was 1.03 B JPY — a change of -63.26% (lower).

Liabilities

376.86 MJPY

YoY

-63.26%

Last updated:

In 2025, PRISM BioLab Co's total liabilities amounted to 376.86 M JPY, a -63.26% difference from the 1.03 B JPY total liabilities in the previous year.

The PRISM BioLab Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2022
65.23 M JPY
Jan 1, 2023
63.41 M JPY
Jan 1, 2024
1.03 B JPY
Jan 1, 2025
376.86 M JPY
The PRISM BioLab Co Liabilities history
YEARLiabilitiesYoY
376.86 MJPY-63.26%
1.03 BJPY+1,517.49%
63.41 MJPY-2.79%
65.23 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRISM BioLab Co Stock analysis

What does PRISM BioLab Co do? PRISM BioLab Co Ltd generates revenue through two distinct business models in the pharmaceuticals sector. The in-house development business focuses on selecting drug discovery targets and creating programs internally using their PepMetics technology platform. The joint development business collaborates with pharmaceutical companies to develop drug discovery programs leveraging their proprietary PepMetics technology. Both models utilize the company's owned drug discovery platform to create new pharmaceutical products. The company's primary clients are pharmaceutical companies seeking to develop new drugs through partnerships with PRISM BioLab's technology. PRISM BioLab's business model centers on its PepMetics technology, which serves as the foundation for both its in-house development and joint development segments. The company builds new drug discovery platforms and develops new drugs through these segments, targeting pharmaceutical companies as their main customers. The firm's research and development activities are conducted using their owned technology, which differentiates their approach in the drug discovery market. The company's revenue streams are derived from pharmaceutical companies that partner with PRISM BioLab for drug discovery programs. By utilizing their PepMetics technology platform, the company creates targeted drug discovery solutions that are developed either internally or in collaboration with pharmaceutical partners. This approach allows PRISM BioLab to generate income through both direct development efforts and collaborative projects with industry clients. PRISM BioLab Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing PRISM BioLab Co's Liabilities

PRISM BioLab Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating PRISM BioLab Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing PRISM BioLab Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

PRISM BioLab Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in PRISM BioLab Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about PRISM BioLab Co stock

The Liabilities of PRISM BioLab Co is 376.86 M JPY in 2025.

The Liabilities of PRISM BioLab Co changed from 1.03 B JPY to 376.86 M JPY, representing a -63.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities PRISM BioLab Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's PRISM BioLab Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — PRISM BioLab Co

All Key Metrics — PRISM BioLab Co